Streptozocin

Drug Overview

Streptozocin is a specialized chemotherapy medication used primarily to treat certain types of cancer that start in the pancreas. It is unique because it is a naturally occurring compound originally found in a type of soil bacteria. In the medical field, it is classified as an antineoplastic antibiotic and an alkylating agent. It is often described as a Targeted Therapy because it has a high affinity for specific cells in the pancreas.

This medication is a vital tool for oncologists managing rare tumors of the endocrine system. It works by seeking out specific cells and interfering with their ability to grow and divide, eventually causing the cancer cells to die.

• Generic name: Streptozocin
• US Brand names: Zanosar
• Drug Class: Alkylating agent; Antineoplastic antibiotic
• Route of Administration: Intravenous (IV) infusion
• FDA Approval Status: FDA Approved

What Is It and How Does It Work? (Mechanism of Action)

Streptozocin works by acting like a “Trojan Horse” to enter specific cells. To understand how it works at the molecular level, we look at its chemical structure, which contains a sugar molecule called glucose attached to a highly reactive chemical group.

1. Cellular Entry: Because of its sugar-like structure, streptozocin is recognized by the GLUT2 transporter. This is a “doorway” on the surface of pancreatic islet cells (specifically beta cells) that normally lets sugar into the cell. This allows the drug to concentrate specifically in these cells, acting as a Targeted Therapy.
2. DNA Damage: Once inside the cell, the drug releases reactive molecules that attach to the cell’s DNA. This process is called alkylation. It creates “cross-links” or breaks in the DNA strands.
3. Stopping Replication: When the DNA is damaged, the cell cannot copy its genetic blueprint. This stops the cancer cell from dividing into two new cells.
4. Activation of Cell Death: The damaged DNA triggers a stress response within the cell. If the damage is too severe to fix, the cell undergoes apoptosis, which is programmed cell death.
5. Enzyme Inhibition: Streptozocin also inhibits several enzymes involved in making new DNA, further preventing the tumor from growing.

FDA-Approved Clinical Indications

Streptozocin is used specifically for tumors that affect the hormone-producing part of the pancreas.

Oncological uses

• Metastatic islet cell carcinoma of the pancreas (pancreatic endocrine tumors).
• Treatment of tumors that are “unresectable,” meaning they cannot be safely removed by surgery.

Non-oncological uses

• There are currently no FDA-approved non-oncological uses for this medication in humans.

Dosage and Administration Protocols

Streptozocin is given as a clear liquid through an IV. The dose is usually calculated based on the patient’s body surface area (square meters) or body weight (kilograms).

Dose Adjustments

Renal (Kidney) Insufficiency: This is the most critical area for streptozocin. If a patient shows signs of kidney stress (such as protein in the urine or high creatinine), the dose must be reduced or the treatment stopped entirely.

Hepatic (Liver) Insufficiency: While the drug is mainly processed by the kidneys, doctors monitor liver function closely. No standard starting dose adjustment is established, but treatment is paused if liver enzymes become severely elevated.

Clinical Efficacy and Research Results

Current clinical study data from 2020 to 2025 continues to support the use of streptozocin as a standard treatment for pancreatic endocrine tumors.

Numerical data from historical and recent retrospective studies show that when streptozocin is combined with other drugs like 5-fluorouracil (5-FU), the “objective response rate” (tumor shrinkage) is approximately 35 percent to 50 percent. Research results indicate that patients who respond well to this treatment can see their “progression-free survival” extend by many months. Recent research from 2024 studies has explored using streptozocin in combination with newer “Smart Drugs” to see if response rates can be pushed above 60 percent. While newer oral therapies exist, streptozocin remains a cornerstone for rapidly growing or symptomatic pancreatic endocrine cancers.

Safety Profile and Side Effects

Black Box Warning

Streptozocin carries a Black Box Warning for severe Renal Toxicity (Kidney Damage). This damage is “dose-related” and “cumulative,” meaning the risk increases with every dose. It can lead to permanent kidney failure if not caught early.

Common side effects

These occur in more than 10 percent of patients:

• Severe nausea and vomiting (can be very intense)
• Diarrhea
• Feeling very tired (fatigue)
• Temporary changes in liver function tests
• Mild anemia or low white blood cell counts

Serious adverse events

• Severe Kidney Failure: Marked by high creatinine and low urine output.
• Secondary Cancers: As an alkylating agent, there is a small long-term risk of developing leukemia.
• Injection Site Reactions: If the drug leaks out of the vein (extravasation), it can cause severe tissue damage or “burning.”
• Severe confusion or depression (rare neurological effects).

Management strategies

To manage nausea, patients are given strong anti-nausea medications before the infusion starts. To protect the kidneys, doctors check a patient’s urine for protein before every single dose. If protein is found, the drug is typically held until the kidneys recover.

Research Areas

Streptozocin is a primary focus in Research Areas involving “Metabolic Oncology.” Scientists are studying how this drug’s sugar-like structure can be used to deliver other “Smart Drugs” directly to pancreatic cells. There is also interest in the field of immunotherapy to see if the cell death caused by streptozocin makes the tumor more “visible” to the body’s natural T-cells. While it is not typically used with stem cell therapies today, researchers are looking at how to protect healthy stem cells in the bone marrow from the drug’s effects during high-dose treatment cycles.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Comprehensive Metabolic Panel (CMP) to check baseline kidney and liver function.
• Urinalysis to check for protein (Proteinuria).
• Complete Blood Count (CBC).
• Baseline imaging (CT or MRI) to measure the tumor.

Precautions during treatment

The drug is very hard on the kidneys. Patients must stay very well-hydrated before and after treatment to help “flush” the drug through the system.

Do’s and Don’ts list

• Do drink plenty of water (8 to 10 glasses) on treatment days.
• Do tell your nurse immediately if you feel any burning or stinging at the IV site.
• Do report any changes in how much you are urinating.
• Don’t skip your scheduled blood or urine tests.
• Don’t take other medications that can hurt the kidneys (like ibuprofen or certain antibiotics) without asking your oncologist.
• Don’t ignore signs of dehydration, such as dark urine or extreme thirst.

Legal Disclaimer

The information in this guide is for educational and informational purposes only and does not constitute medical advice. Streptozocin is a potent chemotherapy drug that must be administered by trained oncology professionals. Always consult with your doctor regarding your specific diagnosis, treatment plan, and potential side effects.